Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01121185 · ClinicalTrials.gov registry record · Phase 2
Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C
A Phase 2 study, sponsored by MassBiologics.
- Terminated
- Registry status
- Phase 2
- Development phase
- 13
- Enrollment target
NCT01121185: Clinical Trial Phase 2 study, sponsored by MassBiologics.
NCT01121185 is a Phase 2 study that was terminated before completion, run by MassBiologics. The registered enrollment target is 13 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01121185, a Phase 2 study, was terminated before completion, sponsored by MassBiologics.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 13 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether a human monoclonal antibody against Hepatitis C (MBL-HCV1) is effective in preventing detectable levels of Hepatitis C virus in patients undergoing liver transplantation due to chronic HCV infection. The study will also determine if MBL-HCV1 is effective in delaying or reducing the amount of detectable HCV in patients after transplant.
Primary Outcome
Serum HCV RNA was measured by Quantitative RT-PCR
Interventions
- BIOLOGICAL MBL-HCV1
- OTHER 0.9% Sodium chloride Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13 participants |
| Start Date | 2010-06 |
| Est. Completion | 2011-06 |
| Phase | Phase 2 |
Why NCT01121185 stopped before completion
NCT01121185 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (90% lower).
The record links to 0 conditions, and to 2 interventions - of which MBL-HCV1 is the first listed.
NCT01121185 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01121185 about?
NCT01121185 is a clinical study titled "Study in Hepatitis C Virus (HCV) Infected Patients Undergoing Liver Transplantation to Evaluate a Human Monoclonal Antibody Against Hepatitis C". The purpose of this study is to determine whether a human monoclonal antibody against Hepatitis C (MBL-HCV1) is effective in preventing detectable levels of Hepatitis C virus in patients undergoing liver transplantation due to chronic HCV infection. The study will also determine if MBL-HCV1 is effec...
What is the current status of trial NCT01121185?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 13 participants. The study started on 2010-06. Estimated completion is 2011-06.
What interventions are being tested in trial NCT01121185?
The interventions under investigation include: MBL-HCV1 (BIOLOGICAL), 0.9% Sodium chloride Placebo (OTHER).
Who is sponsoring clinical trial NCT01121185?
This trial is sponsored by MassBiologics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01121185's enrollment target sits among peer trials
13 1947th of 2000 higher than 53 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03125655 · 13 participants
Regulation of Inflammatory Genes in Psoriasis
- NCT03774446 · 13 participants · Phase 2
Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease
- NCT03830151 · 13 participants · Phase 1
Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors
- NCT04573231 · 13 participants · Phase 2
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia